NICE news at Deltex

The National Institute for Clinical Excellence (NICE) has reviewed the use of oesophageal Doppler monitoring (ODM) and concluded it is now ‘standard clinical practice’. What does that mean? Most of the ODM studies reviewed involved Deltex Medical’s CardioQ monitors. No further studies will now be required by NICE so doctors using CardioQ will no longer have to do so much paperwork. Equally, clinicians who wish to purchase CardioQ can point to the NICE report for support. It is all-round good news for Deltex, whose shares picked up 5p last week to 27.25p, before settling back at 26.25p. They were tipped here in April 2004 (at 24.75p). It looks as if Deltex is finally on its way. Hold.